MOUNTAIN VIEW, Calif., July 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has selected AZ-007 (Staccato zaleplon) for the treatment of insomnia as the next product candidate to move forward into active development.
CARBO Introduces Innovative Non-Radioactive Traceable Proppant
HOUSTON, June 28 /PRNewswire-FirstCall/ -- CARBO (NYSE: CRR) announced today the introduction of CARBONRTâ„¢, an innovative, environmentally responsible development in proppant placement. This technology incorporates a taggant that allows down hole, near wellbore detection of ceramic proppant.
Palatin Technologies, Inc. Announces Positive Preclinical Data with PL-3994 for Asthma Indications
CRANBURY, N.J., June 21 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.
PL-3994 is a proprietary peptide mimetic that binds and activates natriuretic peptide receptor A, a guanylate cyclase.
